Research programme: intraocular therapeutics - Imprimis Pharmaceuticals

Drug Profile

Research programme: intraocular therapeutics - Imprimis Pharmaceuticals

Alternative Names: Epinephrine/lidocaine; Go Dropless; IPI-140; Lidocaine/epinephrine; Lidocaine/phenylephrine combination; Lyophilized epinephrine combination; Moxifloxacin/triamcinolone; Shugarcaine combination; Triamcinolone/moxifloxacin; Triamcinolone/vancomycin; TriMox; TriMox/vancomycin; TriMoxi; TriMoxi/vancomycin; Vancomycin/moxifloxacin/triamcinolone

Latest Information Update: 18 Nov 2014

Price : $50

At a glance

  • Originator Eye Care Northwest; Novel Drug Solutions
  • Developer Imprimis Pharmaceuticals
  • Class Acetanilides; Azabicyclo compounds; Catecholamines; Cyclopropanes; Ethanolamines; Fluorinated steroids; Fluoroquinolones; Glucocorticoids; Glycopeptides; Piperidines; Pregnadienes; Pyrrolidines; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Postoperative infections; Postoperative inflammation

Most Recent Events

  • 18 Nov 2014 Discontinued - Preclinical for Postoperative infections (Prevention) and Postoperative inflammation (Prevention) in USA (Intraocular)
  • 18 Nov 2014 Discontinued - Preclinical for Postoperative inflammation (Prevention) in USA (Intraocular)
  • 28 Aug 2013 Preclinical trials in Postoperative infections in USA (Intraocular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top